Regulatory Approvals, Positive Stock Price Movements, Optimistic Clinical Data, and New Launches and Contracts - Research Report on Johnson & Johnson, Celldex, Isis, Actavis, and Centene

Thu Sep 26, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

Regulatory Approvals, Positive Stock Price Movements, Optimistic Clinical Data, and New Launches and Contracts - Research Report on Johnson & Johnson, Celldex, Isis, Actavis, and Centene

PR Newswire

NEW YORK, September 26, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Celldex Therapeutics Inc. (NASDAQ: CLDX), Isis Pharmaceuticals, Inc. (NASDAQ: Isis), Actavis Inc. (NYSE: ACT), and Centene Corp. (NYSE: CNC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On September 23, 2013, Janssen Biotech, Inc. (Janssen Biotech), one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Johnson & Johnson), announced that the U.S. Food and Drug Administration (FDA) has approved STELARA (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis. According to Janssen Biotech, STELARA is administered as a 45mg subcutaneous injection at weeks 0 and 4, and then every 12 weeks, thereafter. Investigator and Steering Committee member, Alice B. Gottlieb, Triple Board Certified in Dermatology, Rheumatology, and Internal Medicine, M.D., Ph.D, Chief and Dermatologist-in-Chief, Department of Dermatology, Tufts Medical Center said, "It is critical for dermatologists and rheumatologists to be able to offer new and novel treatment options to our adult patients living with psoriatic arthritis, a disease where additional biologic options are very much needed. Therapy that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), two naturally occurring proteins believed to play a role in the development of this debilitating immune-mediated inflammatory disease, could improve patient care." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/07a8_JNJ]

--

Celldex Therapeutics Inc. Research Report

On September 23, 2013, Celldex Therapeutics Inc.'s (Celldex) stock rose sharply to end the day at $32.68, which is 12.85% higher than the previous trading day's closing price of $28.96. Over the previous three trading sessions, Celldex stock has gained 22.12%, strongly outperforming the Nasdaq Composite, which declined 0.48% during the same period. The Full Research Report on Celldex Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b443_CLDX]

--

Isis Pharmaceuticals, Inc. Research Report

On September 21, 2013, Isis Pharmaceuticals, Inc. (Isis) announced data from a Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with familial chylomicronemia syndrome or FCS. The Company stated that in the study, three patients with FCS treated with ISIS-APOCIIIRx achieved substantial reductions in triglycerides with all three patients achieving triglyceride levels below 500 mg/dL, which substantially reduces the risk of an acute pancreatic event. Patients also achieved substantial reductions in apoC-III and apoCIII-associated very low density lipoprotein cholesterol (VLDL-C) particles. Richard Geary, Ph.D., Senior Vice President of Development at Isis, said, "These data presented today are particularly encouraging as we plan to pursue FCS as the initial indication for ISIS-APOCIIIRx in advance of our next indication in patients with severely elevated triglycerides. We believe that the significant unmet medical need for an effective triglyceride-lowering drug for patients with FCS and the robust, consistent effects we observe with ISIS-APOCIIIRx should enable us to rapidly move forward." He added, "We look forward to discussing our Phase 3 plans with regulators and moving into a Phase 3 program next year in both patients with FCS and patients with severely high triglycerides." The Full Research Report on Isis Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/fcfc_ISIS]

--

Actavis Inc. Research Report

On September 16, 2013, Actavis, Inc. (Actavis) announced that it has launched a generic version of Lidoderm (lidocaine tropical patch 5%) as part of an exclusive agreement with Endo Pharmaceuticals Inc. (Endo) and Teikoku Seiyaku Co. Ltd. The Company stated that it has begun shipping the product and believes that under the applicable Hatch Waxman rules, it is entitled to 180 days of marketing exclusivity. Paul Bisaro, President and CEO of Actavis, said, "Thanks to this settlement agreement, consumers across the country are today benefitting from generic competition on Lidoderm® more than two years before the product's patents expire. We are pleased to be able to provide patients with this more affordable treatment option, while offering yet another reminder of how patent settlements have saved and continue to save consumers billions of dollars and ensure the more-timely introduction of generic competition." The Full Research Report on Actavis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4997_ACT]

--

Centene Corp. Research Report

On September 20, 2013, Centene Corp. (Centene) announced that its Massachusetts subsidiary, CeltiCare Health Plan, was notified by the Massachusetts Executive Office of Health and Human Services (EOHHS) that it has been awarded a contract to participate in the MassHealth CarePlus program in all five regions. The Company informed that the contract will be effective October 15, 2013, and coverage will commence on January 1, 2014. As per the contract, the Company will provide comprehensive healthcare services for eligible non-pregnant Medicaid adults in the Northern, Greater Boston, Southern, Central and Western regions and the services will include medical, behavioral health, dental, vision, pharmacy, therapies, and transportation.The Full Research Report on Centene Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e85d_CNC]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.